Safety Alert for Defibrillators / cardioversors, implantable, Profile MD model V

According to Agência Nacional de Vigilância Sanitária (ANVISA), this safety alert involved a device in Brazil that was produced by St Jude Medical Inc Cardiac Rhythm Management Div.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event ID
    507
  • Date
    2002-03-20
  • Event Country
  • Event Source
    ANVISA
  • Event Source URL
  • Notes / Alerts
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Extra notes in the data
    Brazil - 03/20/2002 - The company ST JUDE MEDICAL BRASIL LTDA, informs of the existence of only 3 cardioversors in the national scope, and that already has provided the exchange of 02 two units implanted as a prophylactic measure. As additional data, it also states that statistical forecast is that only 13 of the 771 devices notified worldwide should present some kind of problem. ANVISA / Technovigilance Unit, is monitoring, having documented the name of the establishment, model, nr. series, category and date of implantation of the cardioverters in question.
  • Reason
    In profile md model v cardioversion-defibrillators (icds), 33 nf ceramic capacitors may fail, leading to decreased reliability of the units. the manufacturer initiated the correction by technical memoranda sent to us physicians through federal express dated july 13, 2001. the company states that no death or serious injury occurred due to product failure. two different clinical manifestations of trainer failure can be observed, depending on the location of the trainers. products with a capacitor that fails in the high voltage module may exhibit a rapid loss of sensitivity or hypersensitivity of internally generated interference - or noise, resulting in failure or release of shocks. products with a capacitor that fails in the high voltage module may experience premature battery loss without other clinical manifestations. although the battery voltage may fall rapidly to a value close to or below the optional equipment reset indicator, it stabilizes for several months at a value that the product continues to detect arrhythmias and promote appropriate therapy. some of these products may also exhibit hypersensitivity of internally generated electrical interference or noise that may result in a false tachyarrhythmia detection, but interference decreases during loading and therapy is usually failed without releasing inappropriate shock to patients. these failures occur within 24 months of the date the modules were incorporated into the set of icds; products that have not failed within 24 months will not present a risk of failure at a later date.
  • Action
    Check receipt of the technical memorandum dated July 13, 2001 from St Jude Medical. The manufacturer states that none of the potentially affected ICDs that were not deployed remain on the market and that all units manufactured as of January 2001 are not affected by this problem. They estimate that the anticipated number of additional failures is less than 13. They claim that the decision to switch an ICDs prophylactically depends on clinical judgment. They add, however, that product switching should be considered for patients with products that have suspect trainers in the Low Voltage Module. St Jude will provide replacement products at no charge according to its warranty policy to any physician who decides to replace the products affected by this fix. Any patient who does not have their products changed should be monitored monthly in the remaining months during which additional failures may occur and then every 3 months. In the United States, increased monthly monitoring can occur using St Medical Housecall Transtelephonic Monitoring System with no burden during the 24 month period of remaining risk. For more information on specific patients or for more information regarding this correction, contact your local representative or directly with St Jude Medical's tachycardia technical service department at 1 (468) 474-4147, at U.S. Notify any occurrences associated with these products, to ANVISA, Technovigilance Unit, filling out the Health Product Associated Notifications Form available on the Internet http://www.anvisa.gov.br/tecnovigilancia and send directly online or save the file completed and send by e-mail tecnovigilância@anvisa.gov.br, or print it and send by fax 0xx61-4481257

Manufacturer